ArticleFrontiers in microbiology2022
Molecular Characterization of Penicillin-Binding Protein2x, 2b and 1a of
Article in Frontiers in microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- Prevalence ofHuman vaccines & immunotherapeutics · 2024Pooled it
- Article
- Molecular characterization and correlation with β-lactam resistance of penicillin-binding protein2x, 2b, and 1a ofMicrobiology spectrum · 2026Article
- The Convergence of Antimicrobial Resistance and Virulence inMicroorganisms · 2026Review
- Target Fidelity and Failure: Structure-Activity Relationship of High-Molecular-Mass Penicillin-Binding Proteins (HMM-PBPs) in RefractoryAntibiotics (Basel, Switzerland) · 2026Article
- A case of severeRespiratory medicine case reports · 2026Article
- Review
- Lineage structure and penicillin-binding protein variability in clinicalFrontiers in public health · 2026Article
- Machine learning-based virtual screening and density functional theory characterisation of natural inhibitors targeting mutant PBP2x in Streptococcus pneumoniae.Scientific reports · 2025Article
- Review
- The Evolution of the Antimicrobial Resistance ofAntibiotics (Basel, Switzerland) · 2025Article
- The Changes in the Antibiotic Resistance ofJournal of clinical medicine · 2025Article
- Real-world efficacy and safety of cefepime for pediatric community-acquired pneumonia: a propensity score-matched study.Frontiers in cellular and infection microbiology · 2025Article
- Breaking the resistance: integrative approaches with novel therapeutics against Klebsiella pneumoniae.Archives of microbiology · 2024Review
- Antibacterial Mechanisms and Clinical Impact of Sitafloxacin.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Antimicrobial resistance of clinical bacterial isolates in China: current status and trends.JAC-antimicrobial resistance · 2024Review
- Integrated genomic analysis of antibiotic resistance and virulence determinants in invasive strains ofFrontiers in cellular and infection microbiology · 2023Article
- Clinical Characteristics, Antimicrobial Resistance, and Outcomes of Patients with Invasive Pneumococcal Disease in Ningxia Hui Autonomous Region, China, 2013-2021.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.